These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31157674)

  • 21. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness.
    Clark RE; Xie H; Brunette MF
    J Clin Psychiatry; 2004 Feb; 65(2):151-5. PubMed ID: 15003066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of the efficacy of treatments for bipolar disorder and substance abuse.
    Secades-Álvarez A; Fernández-Rodríguez C
    Rev Psiquiatr Salud Ment; 2017; 10(2):113-124. PubMed ID: 26778814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up.
    Mazza M; Mandelli L; Di Nicola M; Harnic D; Catalano V; Tedeschi D; Martinotti G; Colombo R; Bria P; Serretti A; Janiri L
    J Affect Disord; 2009 May; 115(1-2):27-35. PubMed ID: 18845344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy for schizophrenia and co-occurring substance use disorders.
    Green AI
    Neurotox Res; 2007 Jan; 11(1):33-40. PubMed ID: 17449446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temperament and character dimensions in male patients with substance use disorders: Differences relating to psychiatric comorbidity.
    Marquez-Arrico JE; López-Vera S; Prat G; Adan A
    Psychiatry Res; 2016 Mar; 237():1-8. PubMed ID: 26921044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Atypical Antipsychotics in Bipolar Disorder With Comorbid Substance Dependence: A Systematic Review.
    Sepede G; Lorusso M; Spano MC; Di Nanno P; Di Iorio G; Di Giannantonio M
    Clin Neuropharmacol; 2018; 41(5):181-191. PubMed ID: 30036197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical practice guideline on pharmacological and psychological management of adult patients with bipolar disorder and comorbid substance use.
    González-Pinto A; Goikolea JM; Zorrilla I; Bernardo M; Arrojo M; Cunill R; Castell X; Becoña E; López A; Torrens M; Tirado-Muñoz J; Fonseca F; Arranz B; Garriga M; Sáiz PA; Flórez G; San L
    Adicciones; 2022 Apr; 34(2):142-156. PubMed ID: 34171104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bipolar disorder and gambling disorder comorbidity: current evidence and implications for pharmacological treatment.
    Di Nicola M; De Risio L; Pettorruso M; Caselli G; De Crescenzo F; Swierkosz-Lenart K; Martinotti G; Camardese G; Di Giannantonio M; Janiri L
    J Affect Disord; 2014; 167():285-98. PubMed ID: 24999863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological treatment of schizophrenia with comorbid substance use disorder.
    Azorin JM; Simon N; Adida M; Belzeaux R
    Expert Opin Pharmacother; 2016; 17(2):231-53. PubMed ID: 26635059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive-behavioral therapies for depression and substance use disorders: An overview of traditional, third-wave, and transdiagnostic approaches.
    Vujanovic AA; Meyer TD; Heads AM; Stotts AL; Villarreal YR; Schmitz JM
    Am J Drug Alcohol Abuse; 2017 Jul; 43(4):402-415. PubMed ID: 27494547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substance abuse and bipolar comorbidity.
    Sonne SC; Brady KT
    Psychiatr Clin North Am; 1999 Sep; 22(3):609-27, ix. PubMed ID: 10550858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of substance use disorders on recovery from bipolar depression: Results from the Systematic Treatment Enhancement Program for Bipolar Disorder psychosocial treatment trial.
    Gold AK; Peters AT; Otto MW; Sylvia LG; Magalhaes PVDS; Berk M; Dougherty DD; Miklowitz DJ; Frank E; Nierenberg AA; Deckersbach T
    Aust N Z J Psychiatry; 2018 Sep; 52(9):847-855. PubMed ID: 30047784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of co-occurring substance use on 6 month outcomes for young people seeking mental health treatment.
    Baker KD; Lubman DI; Cosgrave EM; Killackey EJ; Yuen HP; Hides L; Baksheev GN; Buckby JA; Yung AR
    Aust N Z J Psychiatry; 2007 Nov; 41(11):896-902. PubMed ID: 17924242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of short-term olanzapine in patients with bipolar I disorder, with or without comorbidity with substance use disorder.
    Sani G; Kotzalidis GD; Vöhringer P; Pucci D; Simonetti A; Manfredi G; Savoja V; Tamorri SM; Mazzarini L; Pacchiarotti I; Telesforo CL; Ferracuti S; Brugnoli R; Ambrosi E; Caloro M; Del Casale A; Koukopoulos AE; Vergne DE; Girardi P; Ghaemi SN
    J Clin Psychopharmacol; 2013 Apr; 33(2):231-5. PubMed ID: 23422396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic review of interventions for co-occurring substance use disorder and borderline personality disorder.
    Pennay A; Cameron J; Reichert T; Strickland H; Lee NK; Hall K; Lubman DI
    J Subst Abuse Treat; 2011 Dec; 41(4):363-73. PubMed ID: 21742460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of alcohol and illicit substance use on verbal memory among individuals with bipolar disorder.
    Cardoso TA; Bauer IE; Jansen K; Suchting R; Zunta-Soares G; Quevedo J; Glahn DC; Soares JC
    Psychiatry Res; 2016 Sep; 243():225-231. PubMed ID: 27423121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal Course of Clients With Co-occurring Schizophrenia-Spectrum and Substance Use Disorders in Urban Mental Health Centers: A 7-Year Prospective Study.
    Drake RE; Luciano AE; Mueser KT; Covell NH; Essock SM; Xie H; McHugo GJ
    Schizophr Bull; 2016 Jan; 42(1):202-11. PubMed ID: 26294706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders.
    Manwani SG; Szilagyi KA; Zablotsky B; Hennen J; Griffin ML; Weiss RD
    J Clin Psychiatry; 2007 Aug; 68(8):1172-6. PubMed ID: 17854240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual diagnosis: the Depression And Bipolar Support Alliance's Patient Perspective.
    Lewis L
    Biol Psychiatry; 2004 Nov; 56(10):728-9. PubMed ID: 15556116
    [No Abstract]   [Full Text] [Related]  

  • 40. Mental health facilities with ketamine infusion therapy in the United States in 2020: Co-location of dual diagnosis mental health and substance use disorder treatment.
    Ware OD
    Exp Clin Psychopharmacol; 2024 Jun; 32(3):263-269. PubMed ID: 37917509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.